Potential Clinical Value of 5-Hydroxytryptamine Receptor 3C as a Prognostic Biomarker for Lung Cancer

Table 3

Univariate and multivariate analysis of disease-free survival for lung cancer.

Variables	Item	Univariate			Multivariate
		HR	95% CI	value	HR	95% CI	value
Age (y)	>70	1.22	(0.71, 2.12)	0.471	1.29	(0.68, 2.42)	0.438
	≤70	1.00			1.00
Sex	Male	0.90	(0.55, 1.47)	0.680	0.88	(0.48, 1.61)	0.677
	Female	1.00			1.00
Grade	II/III	2.04	(0.52, 1.81)	0.037	1.87	(0.88, 4.00)	0.105
	I	1.00			1.00
T status	T4/T3	0.97	(0.51, 1.64)	0.919	0.95	(0.45, 2.03)	0.901
	T2/T1	1.00			1.00
N status	Positive	2.98	(1.81, 4.90)	<0.001	2.41	(1.42, 4.08)	0.001
	Negative	1.00			1.00
M status	Positive	2.41	(1.37, 4.23)	0.002	0.95	(0.43, 2.13)	0.903
	Negative	1.00			1.00
Histology	Squamous cell carcinoma	1.73	(1.02, 2.96)	0.043	1.94	(1.03, 3.65)	0.041
	Adenocarcinoma	1.00			1.00
Performance	1	2.24	(1.40, 3.58)	0.001	2.16	(1.18, 3.94)	0.012
	0	1.00			1.00
Smoking status	Current	1.06	(0.60, 1.90)	0.835	1.08	(0.49, 2.37)	0.856
	Former	1.07	(0.58, 1.97)	0.840	1.18	(0.57, 2.45)	0.654
	Never	1.00			1.00
HTR3C	High	2.37	(1.42, 3.96)	0.001	2.71	(1.51, 4.85)	0.001
	Low	1.00			1.00

HR = hazard ratio; CI = confidence interval.